|
|
|
| MedNEWS | HOME | |
Lusa - Business News - Portugal: Research, precision medicine critical to get investment - IPO chief
Porto, Portugal, April 16,2024 (Lusa) - The head of the Portuguese Institute of Oncology(IPO) in Porto, a 50-year-old institution, highlighted clinical research and precision medicine as "critical bets" in attracting investment, differentiating care and retaining professionals. "Cancer is a disease that is tending to increase (...). This is an area that requires much greater investment in knowledge that will lead us to better understand the disease and thus develop therapeutic weapons to combat it, offering patients more years with quality of life," said Júlio Oliveira. As part of the 50th anniversary of the Porto IPO, the head of the cancer centre recognised by the European Organisation of Cancer Institutes (OECI), highlighted the commitment of this specialist hospital to integrating research into the continuum of care "not sporadically, but systematically". "For example, the percentage of patients included in clinical trials is a variable for assessing the quality of large centres that want to be reference centres in oncology," he said. IPO do Porto has 481 patients included in clinical trials and 26 of these are phase 1. "It's about giving patients access to new medicines, new therapeutic strategies. This has an impact on improving the organisation, improving the standard of care and, consequently, improving the health results that are obtained," he added. In an interview with the Lusa news agency on Monday, Júlio Oliveira, who has been head of the IPO do Porto since 2022 and has been a doctor at the institution since 2007, also highlighted the commitment to precision medicine in oncology, an area that allows patients, both adults and children, who reach the last line of conventional treatment and from then on no longer have conventional options, to have access to innovative technologies. "IPO do Porto has developed the first precision medicine programme in oncology in Portugal (...). We try to obtain a sort of identity card for the tumour, characterising it biologically to try to find weaknesses in it that can be used to guide treatments. This is done in the context of a clinical trial or using medicines that may be available commercially, but which are only approved for another type of disease than the one the patient has," he described. This programme involves professionals from pathology, human genetics, oncology, paediatrics, surgery, clinical pharmacology, biologists and pharmacists, among others. Around half of the patients being treated in a service open to the whole country come from other hospitals. And 10 to 12 % of the patients studied have shown some molecular alteration that could predispose them to a response to a targeted treatment. Speaking to Lusa, Júlio Oliveira highlighted the regular coordination with centres in France and Spain, as well as, more recently, Norway, Sweden, Finland and Denmark. In addition to precision medicine based on the genomic characterisation of tumours, there is also a commitment to nuclear medicine, in which radiopharmaceuticals are used to treat cancer. "This is a recent investment, but it's the result of decades of work (...). We're going to need more investment so that we can continue to grow," said the head of the centre, noting that last week the IPO do Porto included the world's first patient in a phase 1 clinical trial with a radiopharmaceutical. "This is an achievement for the country. It's an achievement for IPO do Porto," he summarised. Stressing that "this is not bench research", but "technology used for the benefit of the patient", Júlio Oliveira said that "more than expanding the frontiers of knowledge, it is giving access to innovative technologies to cancer patients in Portugal" and left a warning. "This is only possible and only makes sense if there is a vision of organisation in the Portuguese health ecosystem, essentially in the NHS," he said. Still on the subject of organisation, access to care and attracting investment, Júlio Oliveira said that several experts from the IPO do Porto are taking part at European level in drawing up a strategy aimed at reducing imbalances in access to cancer care. "In Portugal, there is also this disparity in care. From screening, which we know is much more widespread in the north than in the south, to the diagnosis and treatment of cancer (...). The concept that is being consolidated is the 'Comprehensive Cancer Care Network', in other words, the creation of comprehensive oncology care networks," he described. Arguing that "the treatment of oncological disease cannot be seen in an island logic", Júlio Oliveira considered that "the standard of care to be offered should not depend on the point of entry into the system". "This is more than referencing. It's about certification. There can be no difference in access if you enter a hospital in Bragança or a centre in Castelo Branco or somewhere in Porto, Lisbon or Coimbra (...). This may seem like a somewhat utopian vision, but any utopia is only a utopia until it has a place. And the Porto IPO has managed to overcome many utopias," he concluded. Organised into 12 pathology clinics, the Porto IPO sees around 10,000 new patients a year, with around 56,000 being followed up. PFT/AYLS // AYLS Lusa Agency : LUSA Date : 2024-04-17 10:29:00
|
||
ANADOLU AJANSI - AA
AGENCE FRANCE PRESSE - AFP
AGENCE MAURITANIENNE D'INFORMATION - AMI
ATHENS NEWS AGENCY/ MACEDONIAN NEWS AGENCY - ANA / MPA
AGENZIA NAZIONALE STAMPA ASSOCIATA
ALGERIE PRESSE SERVICE - APS
ALBANIAN TELEGRAPHIC AGENCY - ATA
CYPRUS NEWS AGENCY - CNA
AGENCIA EFE,S.A. - EFE
FEDERAL NEWS AGENCY - FENA
CROATIAN NEW AGENCY - HINA
LIBYAN NEW AGENCY - LANA
AGENCE MAROCAINE DE PRESSE - MAP
MIDDLE EAST NEWS AGENCY - MENA
NATIONAL NEWS AGENCY - NNA
SLOVENIAN PRESS AGENCY - STA
SYRIAN ARAB NEWS AGENCY - SANA
TANJUG TACNO - TANJUG
AGENCE TUNIS AFRIQUE PRESS- TAP
PALESTINIAN NEWS & INFO AGENCY - WAFA
FEDERATION OF ARAB NEWS AGENCY - FANA>
INTERNATIONAL PRESS SERVICE -IPS
ORGANIZATION OF ASIAN -PACIFIC NEWS AGENCIES - OANA
EUROPEAN ALLIANCE OF NEWS AGENCIES - EANA
ASSOCIATION OF BALKAN NEWS AGENCIES - ABNA
FEDERATION ATLANTIQUE DES AGENCES DE PRESSE AFRICAINES - FAAPA
